［1］Marfella CG,Imbalzano AN．The Chd family of chromatin remodelers［J］．Mutat Res,2007,618(1-2)：30-40．
［2］Wang HP,Xu QZ,Zhou PK.Progress on chromatin remodeling factor CHD［J］.Int J Radiation Med Nuclear Med,2006,30（1）:42-43.［王会平，徐勤枝，周平坤.染色质重构因子CHD蛋白家族的研究进展［J］.国际放射医学核医学杂志,2006，30（1）：42-43.］
［3］Oliver SS,Musselman CA,Srinivasan R,et al.Multivalent recognition of histone tails by the PHD fingers of CHD5［J］.Biochemistry,2012,51(33):6534-6544.
［4］Paul S,Kuo A,Schalch T,et al.Chd5 requires PHD-mediated histone 3 binding for tumor suppression［J］.Cell Rep,2013,3(1):92-102.
［5］Egan CM,Nyman U,Skotte J,et al.CHD5 is required for neurogenesis and has a dual role in facilitating gene xpression and polycomb gene repression［J］.Dev Cell,2013,26(3):223-236.
［6］Thompson PM，Gotoh T，Kok M，et al．CHD5，a new member of the chromodomain gene family,is preferentially expressedin the nervous system［J］．Oncogene,2003,22(7):1002-1011．
［7］Kolla V,Naraparaju K,Zhuang T,et al.The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex［J］.Biochem J,2015,468(2):345-352.
［8］Bagchi A,Papazoglu C,Wu Y,et al.CHD5 is a tumor suppressor at human 1p36［J］.Cell,2007,128(3):459-475.
［9］Brodeur GM.Neuroblastoma:biological insights into a clinical enigma［J］.Nat Rev Cancer,2003,3(3):203-216.
［10］Brodeur GM,Hogarty MD,Mosse YP,et al.Neuroblastoma［A］.Pizzo PA,Poplack DG.Principles and practice of pediatric oncology［M］.Philadelphia,PA:Lippincott,Williams and Wilkins,2011：886-922.
［11］Brodeur GM,Sekhon G,Goldstein MN.Chromosomal aberrations in human neuroblastomas［J］.Cancer,1977,40(5):2256-2263.
［12］Attiyeh EF,London WB,Mosse YP,et al.Chromosome 1p and 11q deletions and outcome in neuroblastoma［J］.N Engl J Med,2005,353:2243-2253.
［13］Brodeur GM,Green AA,Hayes FA,et al.Cytogenetic features of human neuroblastomas and cell lines［J］.Cancer Res,1981,41(11):4678-4686.
［14］Fong CT,Dracopoli NC,White PS,et al.Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas:correlation with N-myc amplification［J］.Proc Natl Acad Sci USA,1989,86(10):3753-3757.
［15］Maris JM,White PS,Beltinger CP,et al.Significance of chromosome 1p loss of heterozygosity in neuroblastoma［J］.Cancer Res,1995,55(20):4664-4669.
［16］White PS,Maris JM,Beltinger C,et al.A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3［J］.Proc Natl Acad Sci USA,1995,92(12):5520-5524.
［17］White PS,Thompson PM,Gotoh T,et al.Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma［J］.Oncogene,2005,24(16):2684-2694.
［18］Fujita T,Igarashi J,Okawa ER,et al.CHD5,a tumor suppressor gene deleted from 1p36.31 in neuroblastomas［J］.J Natl Cancer Inst,2008,100(13):940-949.
［19］Garcia I,Mayol G,Rodriguez E,et al.Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma［J］.Mol Cancer,2010,9:277.
［20］Koyama H,Zhuang T,Light JE,et al.Mechanisms of CHD5 Inactivation in neuroblastomas［J］.Clin Cancer Res,2012,18(6):1588-1597.
［21］Okawa ER,Gotoh T,Manne J,et al.Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas［J］.Oncogene,2008,27(6):803-810.
［22］Li H,Xu W,Huang Y,et al.Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo［J］.Int J Mol Med,2012,30(5):1081-1086.
［23］Bagchi A,Papazoglu C,Wu Y,et al.CHD5 is a tumor suppressor at human 1p36［J］.Cell,2007,128(3):459-475.
［24］Law ME,Templeton KL,Kitange G,et al.Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines［J］.Cancer Genet Cytogenet,2005,160(1):1-14.
［25］Wang L,He S,Tu Y,et al.Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma［J］.J Clin Neurosci,2013,20(7):958-963.
［26］Sonia Mulero-Navarro,Manel Esteller.Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer［J］.J Epigenetics,2008,3(4):210-215.
［27］Han LL,Hou L,Song JL.Genetic polymorphisms of methionine synthase,methylation of CHD5,and their association with breast cancer mobidity［J］.China Oncol,2010,20(4):251-255.［韩琳琳，侯琳，宋金莲.甲硫氨酸合成酶多态性及CHD5基因甲基化与乳腺癌发病的关系［J］.中国癌症杂志,2010,20(4):251-255.］
［28］Wu X,Zhu Z,Li W,et al.Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer［J］.Breast Cancer Res,2012,14(3):R73.
［29］Zhao R,Yan Q,Lv J,et al.CHD5,a tumor suppressor that is epigenetically silenced in lung cancer［J］.Lung Cancer,2012,76(3):324-331.
［30］Mokarram P,Kumar K,Brim H,et al.Distinct high-profile methylated genes in colorectalcancer［J］.PLoS One,2009,4(9):e7012.
［31］Fatemi M,Paul TA,Brodeur GM,et al.Epigenetic silencing of CHD5,a novel tumor-suppressor gene,occurs in early colorectal cancer stages［J］.Cancer,2014,120(2):172-180.
［32］Cai C,Ashktorab H,Pang X,et al.MicroRNA-211 expressionpromotes colorectal cancer cell growthin vitro and in vivo by targeting tumor suppressor CHD5［J］.PLoS One,2012,7(1):e29750.
［33］Zhao R,Wang NS,Huang HL,et al.CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma［J］.Liver International,2014,34:151-160.
［34］Yu L,Gong X,Sun L,et al.miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma［J］.Oncotarget,2015,7:30.
［35］Wang J,Chen H,Fu S,et al.The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma［J］.Oral Oncol,2011,47(7):601-108.
［36］He QY.Study on epigenetic change of CHD5 gene in esophageal cancer［D］.Zheng Zhou:The First Affiliated Hospital of Zhengzhou University,2012：1-47.［何巧玉.食管癌中CHD5基因表观遗传学改变［D］.郑州：郑州大学第一附属医院，2012:1-47.］
［37］Wang X,Lau KK,So LK,et al.CHD5 is down-regulated through promoter hypermethylation in gastric cancer［J］.J Biomed Sci,2009,16:95.
［38］Qu Y,Dang S,Hou P.Gene methylation in gastric cancer［J］.Clin Chim Acta,2013,424:53-65.
［39］Gorringe KL,Choong DY,Williams LH,et al.Mutation and methylation analysis of the chromodomainhelicase-DNA binding 5 gene in ovarian cancer［J］.Neoplasia,2008,10(11):1253-1258.
［40］Wong RR,Chan LK,Tsang TP,et al.CHD5 downregulation associated with poor prognosis in epithelial ovarian cancer［J］.Gynecol Obstet Invest,2011,72(3):203-207.
［41］Zhang Y,Luo ZQ,Du XJ,et al.The relationship between the clinical significance and prognosis of XAF1 CHD5 express deliver convey show communicate and Ki67 in tumor of ovary serous adenocarcinoma［J］.China & Foreign Med Treat,2013,06(a):38-39.［张燕,罗政权,杜秀杰,等.XAF1、CHD5和Ki67在卵巢肿瘤浆液性腺癌中表达的临床意义及与预后的关系［J］.中外医疗,2013,06(a):38-39.］
［42］Du X,Wu T,Lu J,et al.Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma［J］.Clin Transl Oncol,2013,15(3):198-204.
［43］Hall WA,Petrova AV,Colbert LE,et al.Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer［J］.Oncogene,2014,33(47):5450-5456.